Radiat Oncol J.  2012 Dec;30(4):218-225.

Prognostic implications of tumor volume response and COX-2 expression change during radiotherapy in cervical cancer patients

• Noh JM
• Park W
• Huh SJ
• Cho EY
• Choi YL
• Bae DS
• Kim BG

Abstract

PURPOSE
The relationship between treatment outcomes, alteration of the expression of biological markers, and tumor volume response during radiotherapy (RT) in patients with uterine cervical cancer was analyzed.
MATERIALS AND METHODS
Twenty patients with cervical squamous cell carcinoma received definitive RT with (n = 17) or without (n = 3) concurrent chemotherapy. Tumor volumes were measured by three serial magnetic resonance imaging scans at pre-, mid-, and post-RT. Two serial punch biopsies were performed at pre- and mid-RT, and immunohistochemical staining for cyclooxygenase (COX)-2 and epidermal growth factor receptor was performed. The median follow-up duration was 60 months.
RESULTS
The median tumor volume response at mid-RT (V2R) was 0.396 (range, 0.136 to 0.983). At mid-RT, an interval increase in the distribution of immunoreactivity for COX-2 was observed in 8 patients, and 6 of them showed poor mid-RT tumor volume response (V2R > or = 0.4). Four (20%) patients experienced disease progression after 10 to 12 months (median, 11 months). All 4 patients had poor mid-RT tumor volume response (p = 0.0867) and 3 of them had an interval increase in COX-2 expression. Overall survival (OS) and progression-free survival (PFS) decreased in patients with V2R > or = 0.4 (p = 0.0291 for both). An interval increase in COX-2 expression at mid-RT was also associated with a decreased survival (p = 0.1878 and 0.1845 for OS and PFS, respectively).
CONCLUSION
Poor tumor volume response and an interval increase in COX-2 expression at mid-RT decreased survival outcomes in patients with uterine cervical cancer.

Keyword

Uterine cervical neoplasms; Radiotherapy; Volume response; Cyclooxygenase-2

MeSH Terms

Biomarkers
Biopsy
Carcinoma, Squamous Cell
Cyclooxygenase 2
Disease Progression
Disease-Free Survival
Follow-Up Studies
Humans
Magnetic Resonance Imaging
Prostaglandin-Endoperoxide Synthases
Receptor, Epidermal Growth Factor
Tumor Burden
Uterine Cervical Neoplasms
Cyclooxygenase 2
Prostaglandin-Endoperoxide Synthases
Receptor, Epidermal Growth Factor